Skip to main content
SpringerLink
Log in

Boehringer Ingelheim and Gilead Sciences' move to freeze prices on antiretroviral drugs bought by US government agencies has been commended

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. AIDS Healthcare Foundation.Boehringer Ingelheim, Gilead Agree to AIDS Drug Price Freeze. Media Release: 04 Jun 2008. Available from: URL: http://www.aidshealth.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boehringer Ingelheim and Gilead Sciences' move to freeze prices on antiretroviral drugs bought by US government agencies has been commended. Pharmacoecon. Outcomes News 555, 10 (2008). https://doi.org/10.2165/00151234-200805550-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805550-00027

Keywords

Search

Navigation